Expression and immunolocalisation of neutral endopeptidase in prostate cancer.

Expression and immunolocalisation of neutral endopeptidase in prostate cancer.

BACKGROUND: Neutral Endopeptidase (NEP) is a cell surface enzyme that cleaves and inactivates neuropeptides. When present on androgen-dependent prostate cancer (PC) cells, NEP inactivates growth stimulatory neuropeptides. After androgen ablation NEP expression decreases and neuropeptides can enhanc...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Albrecht, M, Mittler, A, Wilhelm, B, Lundwall, A, Lilja, H, Aumüller, G, Bjartell, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	2003

Ähnliche Einträge

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
von: Cao, Y, et al.
Veröffentlicht: (2002)

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
von: Valtonen-André, C, et al.
Veröffentlicht: (2007)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
von: Olsson, A, et al.
Veröffentlicht: (2005)

Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues.
von: Cao, Y, et al.
Veröffentlicht: (2003)

Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues.
von: Bjartell, A, et al.
Veröffentlicht: (2000)

CD1 antibody immunolocalisation in Langerhans' cell histiocytosis.
von: Pritchard, K, et al.
Veröffentlicht: (1993)

Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
von: Bjartell, A, et al.
Veröffentlicht: (2006)

Tumor markers in prostate cancer I: blood-based markers.
von: Shariat, S, et al.
Veröffentlicht: (2011)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
von: Kurek, R, et al.
Veröffentlicht: (2003)

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
von: Dahlman, A, et al.
Veröffentlicht: (2010)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
von: Olsson, A, et al.
Veröffentlicht: (2004)

Screening for prostate cancer.
von: Carlsson, S, et al.
Veröffentlicht: (2012)

Immunolocalisation of sodium channel NaG in the intact and injured human peripheral nervous system.
von: Coward, K, et al.
Veröffentlicht: (2001)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
von: Vickers, A, et al.
Veröffentlicht: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
von: Vickers, A, et al.
Veröffentlicht: (2010)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
von: Ulmert, D, et al.
Veröffentlicht: (2009)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
von: Lilja, H, et al.
Veröffentlicht: (2008)

Screening for prostate cancer: To the editor
von: Carlsson, S, et al.
Veröffentlicht: (2012)

Turning an asparaginyl endopeptidase into a peptide ligase
von: Hemu, Xinya, et al.
Veröffentlicht: (2021)

Urological cancer: Time for another rethink on prostate cancer screening.
von: Vickers, A, et al.
Veröffentlicht: (2012)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
von: Botchorishvili, G, et al.
Veröffentlicht: (2009)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
von: Haese, A, et al.
Veröffentlicht: (2004)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
von: Siivola, P, et al.
Veröffentlicht: (2000)

IgG endopeptidase in highly sensitized patients undergoing transplantation
von: Jordan, S, et al.
Veröffentlicht: (2017)

Prostate cancer: estimating the benefits of PSA screening.
von: Vickers, A, et al.
Veröffentlicht: (2009)

miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
von: Hagman, Z, et al.
Veröffentlicht: (2010)

Circulating biomarkers for prostate cancer.
von: Steuber, T, et al.
Veröffentlicht: (2007)

Screening for prostate cancer: an update.
von: Shariat, S, et al.
Veröffentlicht: (2008)

Screening for prostate cancer: early detection or overdetection?
von: Vickers, A, et al.
Veröffentlicht: (2012)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
von: Lilja, H, et al.
Veröffentlicht: (2011)

Five genetic variants associated with prostate cancer.
von: Vickers, A, et al.
Veröffentlicht: (2008)

THE P-MARK BIOBANK: A EUROPEAN MULTICENTER BIOREPOSITORY FOR PROSTATE CANCER RESEARCH
von: Marsden, G, et al.
Veröffentlicht: (2009)

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
von: Steiner, H, et al.
Veröffentlicht: (2004)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
von: Bangma, C, et al.
Veröffentlicht: (2010)

A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein.
von: Clauss, A, et al.
Veröffentlicht: (2002)

A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein
von: Clauss, A, et al.
Veröffentlicht: (2002)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
von: Lilja, H, et al.
Veröffentlicht: (2008)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
von: Klein, R, et al.
Veröffentlicht: (2012)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
von: Vickers, A, et al.
Veröffentlicht: (2011)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
von: Klein, R, et al.
Veröffentlicht: (2010)